Lineage Cell Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Lineage Cell Therapeutics, Inc. (LCTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-03-05
- Lineage Cell Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2018-09-30 was 0.00%.
- Lineage Cell Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2018-03-31 was 0.00%.
- Lineage Cell Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2017-09-30 was 0.00%.
- Lineage Cell Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2017-03-31 was 0.00%.
- Lineage Cell Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
- Lineage Cell Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- Lineage Cell Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- Lineage Cell Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2025-12-31 | 0.00% 10-K · filed 2026-03-05 | |||
| 2024-12-31 | 0.00% 10-K · filed 2026-03-05 | |||
| 2023-12-31 | 0.00% 10-K · filed 2025-03-10 | |||
| 2023-09-30 | 0.00% 10-Q · filed 2023-11-09 | |||
| 2022-12-31 | 0.00% 10-K · filed 2024-03-07 | |||
| 2022-09-30 | 0.00% 10-Q · filed 2023-11-09 | |||
| 2018-09-30 | 0.00% 10-Q · filed 2018-11-08 | 0.00% 10-Q · filed 2018-11-08 | ||
| 2018-06-30 | 0.00% 10-Q · filed 2018-08-02 | |||
| 2018-03-31 | 0.00% 10-Q · filed 2018-05-10 | |||
| 2017-09-30 | 0.00% 10-Q · filed 2018-11-08 | 0.00% 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | 0.00% 10-Q · filed 2018-08-02 | |||
| 2017-03-31 | 0.00% 10-Q · filed 2018-05-10 | |||
| 2014-12-31 | 0.00% 10-K · filed 2015-03-11 | |||
| 2013-12-31 | 0.00% 10-K · filed 2015-03-11 | |||
| 2012-12-31 | 0.00% 10-K · filed 2014-03-17 | |||
| 2011-12-31 | 0.00% 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |